NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011

Author： Muñoz Miguel Martinez-Armesto Juan Coveñas Rafael

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.22, Iss.7, 2012-07, pp. : 735-746

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

NK-1 Receptor Antagonists: A New Generation of Anticancer Drugs

Mini Reviews in Medicinal Chemistry, Vol. 12, Iss. 7, 2012-06 ,pp. : 593-599

Bentham Science Publishers

Access to resources Recommend Favorite

The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines

By Muñoz Miguel

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 529-540

Springer Publishing Company

Access to resources Recommend Favorite

Transient receptor potential vanilloid-1 antagonists: a survey of recent patent literature

By Voight Eric A Kort Michael E

Expert Opinion on Therapeutic Patents, Vol. 20, Iss. 9, 2010-09 ,pp. : 1107-1122

Informa Healthcare

Access to resources Recommend Favorite

NK 1 (substance P) receptor antagonists - why are they not analgesic in humans?

By Hill R.

Trends in Pharmacological Sciences, Vol. 21, Iss. 7, 2000-07 ,pp. : 244-246

Elsevier

Access to resources Recommend Favorite

Tachykinin NK1 receptor antagonists for the control of chemotherapy-induced nausea and vomiting

By Gale Jeremy D O’Neill Brian T Humphrey John M

Expert Opinion on Therapeutic Patents, Vol. 11, Iss. 12, 2001-12 ,pp. : 1837-1847

Informa Healthcare

Access to resources Recommend Favorite